

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A diagnostic test system ~~[[kit]]~~ for detection of a human cancer cell that expresses glypican-1, comprising:
a binding molecule bound to human glypican-1 protein or mRNA encoding glypican-1 of a cell, wherein the binding molecule is selected from the group consisting of an antibody, [[and]] an antibody fragment, and a nucleic acid capable of hybridizing with the mRNA encoding glypican-1 that binds to human glypican-1, and optionally a reporting molecule attached to the binding molecule-such that a detection method allows detection of the cancer by detection of the presence of the binding molecule via detection of the reporting molecule; and
an interpretive article associated with the binding molecule an instruction that provides information that overexpression of glypican-1 in a tissue as compared to a corresponding healthy tissue as evidenced by binding of the binding molecule to a cell is indicative of a human cancer-cell that overexpresses glypican-1.
2. (currently amended) The diagnostic test system ~~agent~~ of Claim 1, wherein the binding molecule comprises an antibody.
3. (currently amended) The diagnostic test system ~~agent~~ of Claim 2, wherein the antibody is bound to used to detect glypican-1 in a body fluid tissue section.
4. (currently amended) The diagnostic test system ~~agent~~ of Claim 2, wherein the antibody is labeled with a label suitable for use in imaging used to image glypican-1.
5. (currently amended) A therapeutic cell treatment system ~~[[kit]]~~ comprising a therapeutic agent at a concentration effective to slow growth of human cancer cells identified to overexpress glypican-1 in a tissue as compared to a corresponding healthy tissue, wherein the agent comprises a molecule selected from the group consisting of a nucleic acid that hybridizes with mRNA encoding glypican-1, an antibody, and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1,

- cleaving an extracellular region of human glypican-1, and suppressing expression of an extracellular region of human glypican-1, and an interpretive article associated with the therapeutic agent ~~an instruction~~ that provides information that binding of the binding molecule to the cancer cells slows growth of the cancer cells that overexpress glypican-1.
6. (currently amended) The ~~system~~ composition of Claim 5, wherein the molecule comprises an antibody that binds to the extracellular region of glypican-1.
 7. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
 8. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
 9. (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.
 10. (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.
 11. (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
 12. (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.
 13. (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.
 14. (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.

15. (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
16. (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
17. (previously presented) The diagnostic kit of claim 1 wherein the human cancer cell is a pancreatic cancer cell or a breast cancer cell.
18. (previously presented) The therapeutic kit of claim 5 wherein the human cancer cells are pancreatic cancer cells or breast cancer cells.